

Announcement

NeuroSearch's license partner Abbott initiates clinical Phase II study with ABT-894 in Attention Deficit Hyperactivity Disorder (ADHD)

NeuroSearch's development and license partner Abbott has initiated a clinical Phase II study with the drug candidate, ABT-894, for the treatment of Attention Deficit-Hyperactivity Disorder (ADHD) in adults. The first patients have been enrolled and dosed in the study.

The clinical Phase II study is a randomized, double-blind and placebo-controlled dose-ranging trial to evaluate the efficacy of ABT-894 in ADHD patients. For further study details please go to: <http://www.clinicaltrials.gov/ct/show/NCT00429091?order=1>.

ABT-894 is a subtype selective modulator of Neuronal Nicotinic Acetylcholine receptors (NNR), which had promising effects in pre-clinical models for pain and other central and peripheral nervous system diseases. It has successfully completed a number of Phase I single and multiple dosing studies. An additional clinical Phase II programme with ABT-894 is planned in patients suffering from diabetic neuropathy (severe chronic pain conditions).

Under the terms of the license agreement, Abbott is responsible for the clinical development and commercialization of ABT-894 and will finance all development costs. NeuroSearch will receive milestone payments as well as royalties on sales.

The initiation of the Phase II study with ABT-894 does not change NeuroSearch's financial expectations for 2007 of a pretax loss of DKK 80 – 100 million as stated in the 2006 announcement of 5 March 2007.

Asger Aamund
Chairman of the Board

Contact persons:

Flemming Pedersen, CEO
Phone: +45 4460 8214 or +45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications
Phone: +45 4460 8212 or +45 4017 5103

NeuroSearch is a Scandinavian biopharmaceutical company listed on the Copenhagen Stock Exchange (NEUR). Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and transporters. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. Eight drug programmes are in clinical development: ACR16 for the treatment of Huntington's disease (under preparation for Phase III), tesofensine for the treatment of obesity/type 2 diabetes (Phase II), NS2359 for the treatment of depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 for the treatment of epilepsy and pain (Phase II), ABT-894 for the treatment of ADHD (Phase II) and neuropathic pain (Phase I) in partnership with Abbott, ACR16 for the treatment of schizophrenia (Phase I) in partnership with Astellas, and ACR325 for the treatment of psychoses such as bipolar disorder (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and has equity interests in several biotech companies.